Compare PTY & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTY | NRIX |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | 357 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2002 | 2020 |
| Metric | PTY | NRIX |
|---|---|---|
| Price | $11.69 | $23.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $11.58 | $8.20 |
| 52 Week High | $14.69 | $25.09 |
| Indicator | PTY | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 58.98 |
| Support Level | $11.62 | $14.63 |
| Resistance Level | $11.98 | $24.98 |
| Average True Range (ATR) | 0.09 | 1.21 |
| MACD | -0.04 | -0.26 |
| Stochastic Oscillator | 18.18 | 52.40 |
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.